REG - Synairgen plc - Grant of Options
RNS Number : 9515ASynairgen plc07 June 2021Press Release
Synairgen plc
('Synairgen' or the 'Company')
Grant of options
Southampton, UK - 7 June 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 4 June 2021 the Board of Synairgen granted options ('Options') over 831,725 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 0.42 per cent. of the Company's issued share capital.
Following this grant, Synairgen has 9,503,004 options in issue, representing 4.75 per cent. of the Company's issued share capital.
Included in the number of Options granted on 4 June 2021, the following Options were issued to directors:
Director
Options Issued
Richard Marsden
135,626
Dr. Phillip Monk
97,953
John Ward
105,487
Following the issue of the Options, the interests of the directors of the Company at
4 June 2021 are as follows:
Director
Total options
Ordinary shares
Total interest
Percentage holding of fully diluted share capital
Richard Marsden
2,817,576
754,667
3,572,243
1.71%
Dr. Phillip Monk
2,046,535
244,600
2,291,135
1.09%
John Ward
2,262,106
514,907
2,777,013
1.33%
Simon Shaw
-
1,531,239
1,531,239
0.73%
Iain Buchanan
-
112,741
112,741
0.05%
Dr. Bruce Campbell
-
322,830
322,830
0.15%
Prof. Sir Stephen Holgate
-
886,931
886,931
0.42%
In addition, Jody Brookes, Richard Hennings and Victoria Tear, persons disclosing managerial responsibilities, were granted 62,460, 242,568 and 49,968 Options respectively on the same terms as above. The balance of the Options were granted to a number of employees.
The Options are issued under the Company's Long Term Incentive Plans and are exercisable up to 3 June 2031, subject to the achievement of appropriate performance criteria.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR')
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Carina Jurs
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MK Strategies, LLC (US Media Relations)
Mary Conway
Tel: +1 516 606 6545
Notes for Editors
About Synairgen
Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.
Synairgen is currently focused on developing its product candidate, SNG001 (inhaled interferon beta) for the treatment of COVID-19. SNG001 is potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. The Company is evaluating nebulised SNG001 in its Phase III clinical programme, which has been deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). SNG001 has also been granted Fast Track status from the US Food and Drug Administration (FDA). In a Phase II trial, COVID-19 patients with marked/severe breathlessness demonstrated a threefold greater chance of recovery when treated with SNG001 versus placebo.
Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
1.
Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)
Name
Richard Marsden
2.
Reason for notification
a)
Position / status
Chief Executive Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Synairgen plc
b)
LEI
213800IMMTOPPDF8HD24
4.
Details of the transaction(s):
a)
Description of the financial instrument
Identification code
Options over ordinary shares of 1p each
GB00B0381Z20
b)
Nature of the transaction
Award of Options under the Company's share plans
c)
Price(s) and volume(s)
135,626 Options awarded
d)
Aggregated information
Aggregated volume Price
n/a
e)
Date of the transaction
4 June 2021
f)
Place of the transaction
Outside a trading venue
1.
Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)
Name
Dr Phillip Monk
2.
Reason for notification
a)
Position / status
Chief Scientific Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Synairgen plc
b)
LEI
213800IMMTOPPDF8HD24
4.
Details of the transaction(s):
a)
Description of the financial instrument
Identification code
Options over ordinary shares of 1p each
GB00B0381Z20
b)
Nature of the transaction
Award of Options under the Company's share plans
c)
Price(s) and volume(s)
97,953 Options awarded
d)
Aggregated information
Aggregated volume Price
n/a
e)
Date of the transaction
4 June 2021
f)
Place of the transaction
Outside a trading venue
1.
Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)
Name
John Ward
2.
Reason for notification
a)
Position / status
Chief Financial Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Synairgen plc
b)
LEI
213800IMMTOPPDF8HD24
4.
Details of the transaction(s):
a)
Description of the financial instrument
Identification code
Options over ordinary shares of 1p each
GB00B0381Z20
b)
Nature of the transaction
Award of Options under the Company's share plans
c)
Price(s) and volume(s)
105,487 Options awarded
d)
Aggregated information
Aggregated volume Price
n/a
e)
Date of the transaction
4 June 2021
f)
Place of the transaction
Outside a trading venue
1.
Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)
Name
Jody Brookes
2.
Reason for notification
a)
Position / status
Head of Clinical Operations
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Synairgen plc
b)
LEI
213800IMMTOPPDF8HD24
4.
Details of the transaction(s):
a)
Description of the financial instrument
Identification code
Options over ordinary shares of 1p each
GB00B0381Z20
b)
Nature of the transaction
Award of Options under the Company's share plans
c)
Price(s) and volume(s)
62,460 Options awarded
d)
Aggregated information
Aggregated volume Price
n/a
e)
Date of the transaction
4 June 2021
f)
Place of the transaction
Outside a trading venue
1.
Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)
Name
Victoria Tear
2.
Reason for notification
a)
Position / status
Head of Laboratories
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Synairgen plc
b)
LEI
213800IMMTOPPDF8HD24
4.
Details of the transaction(s):
a)
Description of the financial instrument
Identification code
Options over ordinary shares of 1p each
GB00B0381Z20
b)
Nature of the transaction
Award of Options under the Company's share plans
c)
Price(s) and volume(s)
49,968 Options awarded
d)
Aggregated information
Aggregated volume Price
n/a
e)
Date of the transaction
4 June 2021
f)
Place of the transaction
Outside a trading venue
1.
Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')
a)
Name
Richard Hennings
2.
Reason for notification
a)
Position / status
Chief Commercial Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Synairgen plc
b)
LEI
213800IMMTOPPDF8HD24
4.
Details of the transaction(s):
a)
Description of the financial instrument
Identification code
Options over ordinary shares of 1p each
GB00B0381Z20
b)
Nature of the transaction
Award of Options under the Company's share plans
c)
Price(s) and volume(s)
242,568 Options awarded
d)
Aggregated information
Aggregated volume Price
n/a
e)
Date of the transaction
4 June 2021
f)
Place of the transaction
Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHFFMBTMTIMBMB
Recent news on Synairgen
See all newsREG - Synairgen plc - Interim Results
AnnouncementREG - Synairgen plc - Appointment of New Chairman and Notice of AGM
AnnouncementREG - Synairgen plc - Board Change
AnnouncementREG - Synairgen plc - 2023 Full Year Results
AnnouncementREG - Synairgen plc - Grant of Options
Announcement